An Enzymatically Active A Domain Is Required for Cholera-Like Enterotoxins to Induce a Long-Lived Blockade on the Induction of Oral Tolerance: New Method for Screening Mucosal Adjuvants

Infection and Immunity

Volumn 71, Issue 12, 2003, Pages 6850-6856

  Bagley, Kenneth C ^a,b   Abdelwahab, Sayed F ^a,b   Tuskan, Robert G ^a   Lewis, George K ^a,b,c  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ADJUVANT; CHOLERA LIKE ENTEROTOXIN; CHOLERA TOXIN; ENTEROTOXIN; HEAT LABILE TOXIN; LYMPHOCYTE ANTIGEN RECEPTOR; OVALBUMIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERANCE; ENZYME INDUCTION; ESCHERICHIA COLI; MOUSE; MUCOSA; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECEPTOR BLOCKING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; BACTERIAL TOXINS; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNIZATION SCHEDULE; MICE; MICE, INBRED BALB C; MUTATION; OVALBUMIN;

EID: 0345283111     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.12.6850-6856.2003     Document Type: Article

References (40)

1. Agren, L., B. Lowenadler, and N. Lycke. 1998. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 76:280-287.
2. Agren, L., E. Sverremark, L. Ekman, K. Schon, B. Lowenadler, C. Fernandez, and N. Lycke. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164:6276-6286.
3. Agren, L. C., L. Ekman, B. Lowenadler, and N. Y. Lycke. 1997. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin Al subunit. J. Immunol. 158:3936-3946.
4. Bagley, K. C., M. T. Shata, D. Y. Onyabe, A. L. DeVico, T. R. Fouts, G. K. Lewis, and D. M. Hone. 2003. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine 21:3335-3341.
5. Bagley, K. C., S. F. Abdelwahab, R. G. Tuskan, T. R. Fouts, and G. K. Lewis. 2002. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect. Immun. 70:5533-5539.
6. Blanchard, T. G., N. Lycke, S. J. Czinn, and J. G. Nedrud. 1998. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 94:22-27.
7. Cassel, D., and Z. Selinger. 1977. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc. Natl. Acad. Sci. USA 74:3307-3311.
8. Chen, Y., J. Inobe, R. Marks, P. Gonnella, V. K. Kuchroo, and H. L. Weiner. 1995. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 376:177-180. (Erratum, 377:257.)
9. + cells mediate active suppression. J. Immunol. 155:910-916.
10. Covone, M. G., M. Brocchi, E. Palla, W. Dias da Silveira, R. Rappuoli, and C. L. Galeotti. 1998. Levels of expression and immunogenicity of attenuated Salmonella enterica serovar Typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin. Infect. Immun. 66:224-231.
11. de Haan, L., W. R. Verweij, I. K. Feil, M. Holtrop, W. G. Hol, E. Agsteribbe, and J. Wilschut. 1998. Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology 94:424-430.
12. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
13. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenghini, R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92:1644-1648.
14. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 65:2821-2828.
15. Fujihashi, K., T. Koga, F. W. van Ginkel, Y. Hagiwara, and J. R. McGhee. 2002. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20:2431-2438.
16. Fukuta, S., J. L. Magnani, E. M. Twiddy, R. K. Holmes, and V. Ginsburg. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect. Immun. 56:1748-1753.
17. Ghiara, P., M. Rossi, M. Marchetti, A. Di Tommaso, C. Vindigni, F. Ciampolini, A. Covacci, J. L. Telford, M. T. De Magistris, M. Pizza, R. Rappuoli, and G. Del Giudice. 1997. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 65:4996-5002.
18. Giuliani, M. M., G. Del Giudice, V. Giannelli, G. Dougan, G. Douce, R. Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132.
19. Hazes, B., and R. J. Read. 1997. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36:11051-11054.
20. Heyningen, S. V. 1974. Cholera toxin: interaction of subunits with ganglioside GM1. Science 183:656-657.
21. Isaka, M., Y. Yasuda, S. Kozuka, Y. Miura, T. Taniguchi, K. Matano, N. Goto, and K. Tochikubo. 1998. Systemic and mucosal immune responses of mice to aluminum-adsorbed or aluminum-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine 16:1620-1626.
22. Khoury, S. J., W. W. Hancock, and H. L. Weiner. 1992. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176:1355-1364.
23. Lycke, N., and J. Holmgren. 1987. Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand. J. Immunol. 25:407-412.
24. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308.
25. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
26. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dougan, R. Rappuoli, and P. Ghiara. 1998. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16:33-37.
27. Melamed, D., and A. Friedman. 1993. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur. J. Immunol. 23:935-942.
28. Ohtomo, N., T. Muraoka, A. Tashiro, Y. Zinnaka, and K. Amako. 1976. Size and structure of the cholera toxin molecule and its subunits. J. Infect. Dis. 133(Suppl.):31-40.
29. Pizza, M., M. M. Giuliani, M. R. Fontana, G. Douce, G. Dougan, and R. Rappuoli. 2000. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. Int. J. Med. Microbiol. 290:455-461.
30. Porgador, A., H. F. Staats, Y. Itoh, and B. L. Kelsall. 1998. Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. Infect. Immun. 66: 5876-5881.
31. Ryan, E. J., E. McNeela, M. Pizza, R. Rappuoli, L. O'Neill, and K. H. Mills. 2000. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the non-toxic AB complex and the enzyme activity. J. Immunol. 165:5750-5759.
32. Tamura, S., H. Funato, T. Nagamine, C. Aizawa, and T. Kurata. 1989. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB, Vaccine 7:503-505.
33. Tomasi, T. B., Jr. 1980. Oral tolerance. Transplantation 29:353-356.
34. Vajdy, M., and N. Y. Lycke. 1992. Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 75:488-492.
35. Verhasselt, V., C. Buelens, F. Willems, D. De Groote, N. Haeffner-Cavaillon, and M. Goldman. 1997. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 158:2919-2925.
36. Weiner, H. L., A. Friedman, A. Miller, S. J. Khoury, A. al-Sabbagh, L. Santos, M. Sayegh, R. B. Nussenblatt, D. E. Trentham, and D. A. Hafler. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 12:809-837.
37. Whitacre, C. C., I. E. Gienapp, C. G. Orosz, and D. M. Bitar. 1991. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147:2155-2163.
38. Williamson, E., G. M. Westrich, and J. L. Viney. 1999. Modulating dendritic cells to optimize mucosal immunization protocols. J. Immunol. 163:3668-3675.
39. Wu, H. Y., and M. W. Russell. 1998. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16:286-292.
40. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185:1203-1210.